1. National Comprehensive Cancer Network (2017). Stage IV Breast Cancer Guidelines Version 1.0.
https://www.nccn.org/patients/guidelines/stage_iv_breast/index.html#
. Accessed 3/27/17.
2. Smith, I. (2006). Goals of treatment for patients with metastatic breast Cancer. Seminars in Oncology, 33(Suppl 2), 2–5.
https://doi.org/10.1053/j.seminoncol.2005.07.030.
3. US Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims; availability. Federal Register, 74(235), 65132–65133.
4. Zagadailov, E., Fine, M., & Shields, A. (2013). Patient-reported outcomes are changing the landscape in oncology care: Challenges and opportunities for payers. American Health & Drug Benefits, 6(5), 264–274.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, & Center for Biologics Evaluation and Research (2015). Guidance for Industry: Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics.